- ACCP live tweets
- Access Pharmaceuticals Insiders
- ACCP/ACCP.OB information
- Access Pharmaceuticals News
ACCP
$ACCP - technicals support buying at $2.75 http://bit.ly/9Se9IX
ACCP
$ACCP - technicals support buying at $2.75 http://bit.ly/9Se9IX
ACCP
RT @Accesspharma: Updated overview on Access Pharma, by Mike Havrilla at BioMedReports.com ... http://tinyurl.com/yez7b9d $ACCP #cancer
ACCP
RT @Accesspharma: RT @mikehavrilla: Updated Executive Summary for Access Pharma (OTC: ACCP.OB) http://bit.ly/8ZVzz2 $ACCP
ACCP
RT @mikehavrilla: Updated Executive Summary for Access Pharma (OTC: ACCP.OB) http://bit.ly/8ZVzz2 $ACCP
ACCP
@Jarviso9wb Thanks for the mention ... will RT ... Jeff Davis ... $ACCP
ACCP
RT @mozartom: $ACCP.OB / Access Pharma: executive summary, product / pipeline updates at http://www.proactivenewsroom.com/access-pharma
ACCP
Updated overview on Access Pharma, by Mike Havrilla at BioMedReports.com ... http://tinyurl.com/yez7b9d $ACCP #cancer
ACCP
$ACCP.OB $RODM // Updated Executive Summary, Pending Milestones for Access Pharma // http://soc.li/0MhMZxg
ACCP
RT @Accesspharma: RT @mikehavrilla: $ACCP.OB / Access Pharma: executive summary, product / pipeline updates at http://www.proactivenewsroom.
ACCP
Access Pharma ($ACCP) presentation from OneMedPlace forum in San Francisco last month .... http://tinyurl.com/yctgpwe $ACCP #cancer
ACCP
RT @mikehavrilla: $ACCP.OB / Access Pharma: executive summary, product / pipeline updates at http://www.proactivenewsroom.com/access-pharma
ACCP
@otcnewswire Thanks for the Access Pharma ($ACCP) mention ...
ACCP
$ACCP: Initiated program applying Cobalamin platform to siRNA drug delivery: http://bit.ly/cJFQXg
ACCP
$ACCP.OB / Access Pharma: executive summary, product / pipeline updates at http://www.proactivenewsroom.com/access-pharma
Access Pharmaceuticals Inc. - ACCP Insiders
No Insiders
We have no insiders for Access Pharmaceuticals right now.
Know someone who is an insider on Access Pharmaceuticals Inc.?
Let us know.
Access Pharmaceuticals Inc. - ACCP/ACCP.OB information
Access Pharmaceuticals, Inc. a biopharmaceutical company, together with its subsidiaries, engages in the development of novel therapeutics for the treatment of cancer and supportive care of cancer patients. The company’s products include MuGard, a nanopolymer formulation for the management of oral mucositis, a frequent side-effect of cancer therapy. Its lead development candidate for the treatment of cancer includes ProLindac, a Phase II clinical trial candidate for the treatment of ovarian cancer. The company’s products under pre-clinical stage comprise Cobalamin, an oral drug delivery technology for the oral delivery of insulin; and Angiolix, a humanized monoclonal antibody, which acts as ......
www.accesspharma.com
10 Employees
Founded in 1988
ACCESS PHARMACEUTICALS INC (ACCP:OTC BB)
LAST $1.95 USD
CHANGE TODAY 0.00 0.00%
VOLUME 21.9K
As of 8:10 PM 07/30/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of ACCESS PHARMACEUTICALS INC (ACCP)
|
OPEN
$1.90
|
PREVIOUS CLOSE
$1.95
|
|
|
DAY HIGH
$1.95
|
DAY LOW
$1.90
|
|
|
52 WEEK HIGH
08/3/09 - $4.88
|
52 WEEK LOW
07/13/10 - $1.75
|
|
|
MARKET CAP
30.1M
|
AVERAGE VOLUME 10 D
26.3K
|
|
|
EPS TTM
$-0.90
|
SHARES OUTSTANDING
15.5M
|
|
|
ACCP Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
Key developments for ACCESS PHARMACEUTICALS INC (ACCP)
Access Pharmaceuticals Inc. - Special/M&A Call
07/29/2010
To provide an update on the company's strategy and activities surrounding the official launch its lead product, MuGard in North America
Access Pharmaceuticals Signs Exclusive Specialty Distribution Agreement with BioScrip Inc
07/20/2010
Access Pharmaceuticals Inc. announced that it has signed an exclusive specialty distribution agreement with BioScrip Inc. for its product, MuGard, an FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of radiotherapy and/or chemotherapy. The agreement aligns the Company with comprehensive access to BioScrip's nationwide distribution platform and the ability to leverage the company's extensive physician relationships, 110 BioScrip specialty pharmacies, mail distribution capability and diversified payor network.
Access Pharmaceuticals Signs Agreement with Major Biotech Company to Develop Oral Formulations of Injectable Drug
07/15/2010
Access Pharmaceuticals Inc. has entered into a pre-licensing feasibility agreement with a leading biotechnology company to develop an oral formulation of its currently-marketed, proprietary injectable drugs. Access will utilize its proprietary Cobalamin Oral Drug Delivery Technology to develop oral formulations of the drug for pre-clinical testing. Although the terms of the agreement have not been disclosed, Access indicated that any successful formulation developed will be subject to a subsequent full-licensing agreement. The company reported that its novel Cobalamin-coated insulin containing nanoparticle formulations delivered orally provided a pharmacological response (lowering of blood glucose levels in animal models) equivalent to greater than 80% of that achieved by insulin delivered subcutaneously. The company believes the substantial oral bioavailability found underscores the formulation's potential for clinical development and ultimate commercialization. Access' worldwide-exclusive patented Cobalamin(TM) technology utilizes the body's natural vitamin B12 oral uptake to facilitate oral absorption of pharmaceuticals by a "Trojan horse" mechanism.
ACCP Competitors
| Company | Last | Change | |
| No competitor information is available for ACCP. | |||
| Market data is delayed at least 15 minutes. | |||
Industry Analysis
| Valuation | ACCP | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 69.7x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 49.3x |
|
|
ACCP |
||
|
ACCP transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
Access Pharmaceuticals Inc. - ACCP/ACCP.OB news
Access Pharmaceuticals to Host North American MuGard Commercialization Update Conference Call for Investors
2010-07-30 01:13:36
Keywords: Access Pharmaceuticals to Host North American MuGard Commercialization Update Conference Call for Investors, accp.ob
Quote: DALLAS and NEW YORK, July 29ACCESS PHARMACEUTICALS, INC. ACCP.obNews), a biopharmaceutical company specializing in products for cancer and supportive care, today announced that it will host a conference call at 11:00 a.m. EDT on August 3rd, to provide an update on the Company's strategy and activities surrounding the official launch its lead product, MuGard in North America. Â Interested parties may participate by dialing 877-407-4019 (US) or 201-689-8337 (International) approximately five to ...Read article
Zacks Investment Research Issues Research Update on Access Pharmaceuticals
2010-07-29 05:29:00
Keywords: Zacks Investment Research Issues Research Update on Access Pharmaceuticals, accp.ob
Quote: DALLAS and NEW YORK, July 28ACCESS PHARMACEUTICALS, INC. ACCP.obNews), a biopharmaceutical company specializing in products for cancer and supportive care, announced today that Zacks Investment Research has issued a research update summarizing some of the recent positive developments that the Company has been able to achieve which have led to reiteration of the 'Outperform' rating on ACCP and a six-twelve month price target of $8.00.http://www.accesspharma.com/downloads/analyst-reports/ACCP-Zack...Read article
Access Pharmaceuticals Signs Agreement With Major Biotech Company to Develop Oral Formulations of Leading Injectable Drug
2010-07-16 05:39:58
Keywords: Access Pharmaceuticals Signs Agreement With Major Biotech Company to Develop Oral Formulations of Leading Injectable Drug, accp.ob
Quote: DALLAS and NEW YORK, July 15 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. ACCP.obNews), Cobalamin Oral Drug Delivery Technology to develop oral formulations of the drug for pre-clinical testing. Although the terms of the agreement have not been disclosed, Access indicated that any successful formulation developed will be subject to a subsequent full-licensing agreement. Access recently reported that its novel Cobalamin-coated insulin containing nanoparticle formulations delivered orall...Read article
Access Pharmaceuticals, Inc. to Present at One Med Forum Conference in New York City
2010-06-28 08:41:09
Keywords: Access Pharmaceuticals, Inc. to Present at One Med Forum Conference in New York City, accp.ob
Quote: DALLAS and NEW YORK, June 28ACCESS PHARMACEUTICALS, INC.ACCP.obNews) President and CEO Jeffrey B. Davis will present at the One Med Forum: Emerging Company Finance Conference on Wednesday, June 30th at 9:20 AM ET. Â The conference is being held at the Roosevelt Hotel in New York City. Â MuGardoral mucositis, a debilitating side effect of many anticancer treatments. Â Access Pharmaceuticals, Inc. is gearing up for the North American commercial launch set for late summer. http://www.onemedpl...Read article
Access Pharmaceuticals, Inc. Presents MuGard Clinical Experience at MASCC Conference
2010-06-25 04:14:56
Keywords: Access Pharmaceuticals, Inc. Presents MuGard Clinical Experience at MASCC Conference, accp.ob
Quote: DALLAS and NEW YORK, June 24ACCESS PHARMACEUTICALS, INC.ACCP.obNews), a biopharmaceutical company specializing in products for cancer and supportive care, is presenting a scientific poster today at the Multinational Association of Supportive Care in Cancer (MASCC) Conference in Vancouver, B.C. The poster presentation, co-authored by Dr. David Nowotnik of Access Pharmaceuticals and Dr. Caroline Dumas of SpePharm Holdings, summarizes MuGard clinical experience from cancer patients globally undergo...Read article
Access Pharma Sponsors Oral Mucositis Symposium Today for MASCC Conference Attendees
2010-06-23 06:41:01
Keywords: Access Pharma Sponsors Oral Mucositis Symposium Today for MASCC Conference Attendees, accp.ob
Quote: DALLAS and NEW YORK, June 22ACCESS PHARMACEUTICALS, INC.ACCP.obNews), a biopharmaceutical company specializing in products for cancer and supportive care, is sponsoring an Oral Mucositis Symposium today for researchers and health care professionals attending the Multinational Association of Supportive Care in Cancer (MASCC) Conference in Vancouver, B.C.oral mucositis.  The OM Symposium is being held from 8:30 AM – 5:30 PM at the British Columbia Cancer Research Centre in Vancouver.MuGa...Read article
Access Pharma Initiates US MuGard Sampling Program with Leading Oncology Groups
2010-06-16 08:00:33
Keywords: Access Pharma Initiates US MuGard Sampling Program with Leading Oncology Groups, accp.ob
Quote: DALLAS and NEW YORK, June 15ACCESS PHARMACEUTICALS, INC. ACCP.obNewsoral mucositis, a debilitating side effect of many anticancer treatments. Â http://photos.prnewswire.com/prnh/20100615/SF20833)http://www.newscom.com/cgi-bin/prnh/20100615/SF20833)Sampling efforts for the company include providing large oncology groups with MuGard kits containing six weeks' worth of MuGard therapy for patients undergoing radiation and chemotherapy. Through these oncology groups, Access Pharma initially will pr...Read article
Access Pharma Presents at the California NanoSystems Institute Conference Focused on Targeted Delivery of RNAi Therapeutics
2010-06-11 05:35:32
Keywords: Access Pharma Presents at the California NanoSystems Institute Conference Focused on Targeted Delivery of RNAi Therapeutics, accp.ob
Quote: DALLAS, June 10ACCESS PHARMACEUTICALS, INC. ACCP.obNews), a biopharmaceutical company specializing in products for cancer and supportive care, announced that its Senior VP of R&D, David NowotnikNovel Nanodelivery of siRNA and miRNA Symposium, hosted by the California NanoSystems Institute (CNSI) of UCLA. Access Pharma's invited oral presentation and its poster presentation will highlight the cell targeting aspects of the Company's proprietary Cobalamin technology and the progress made by its sci...Read article
ACCESS PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
2010-05-31 04:02:57
Quote: Read article
Zacks Investment Research Initiates Independent Coverage on Access Pharma
2010-05-20 03:08:29
Keywords: Zacks Investment Research Initiates Independent Coverage on Access Pharma, accp.ob
Quote: DALLAS and NEW YORK, May 19 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. ACCP.obNews), a biopharmaceutical company specializing in products for cancer and supportive care, announced today that Zacks Investment Research initiated coverage on the Company with an "Outperform" and a 12-month price target of $8.00.The report can be viewed by clicking on following link: http://www.accesspharma.com/downloads/analyst-reports/ACCPInitiation.pdfAbout Zacks:Founded in 1978 in Chicago, Zacks Inves...Read article
ACCESS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
2010-05-18 02:53:42
Quote: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
OVERVIEW
Access Pharmaceuticals, Inc. (together with our subsidiaries, "we", "Access" or
the "Company") is a Delaware corporation. We are an emerging biopharmaceutical
company focused on developing a range of pharmaceutical products primarily based
upon our nanopolymer chemistry technologies and other drug delivery
technologies. We currently have one approved product, two prod...Read article
Access Pharmaceuticals to Present MuGard Data and Host Oral Mucositis Symposium at MASCC Conference in June
2010-04-22 01:32:00
Keywords: Access Pharmaceuticals to Present MuGard Data and Host Oral Mucositis Symposium at MASCC Conference in June, accp.ob
Quote: DALLAS and NEW YORK, April 21ACCESS PHARMACEUTICALS, INC.ACCP.obNews), a biopharmaceutical company specializing in products for cancer and supportive care, announced today that it will present data from the ongoing work involving its lead product, MuGard, and host an oral mucositis symposium at the MASCC conference being held in Vancouver, B.C. on June 24-26, 2010MuGardoral mucositis, a debilitating side effect of many anticancer treatments. Â "We are delighted to have the opportunity to host ...Read article
Access Pharma's CEO Interviewed By Proactive Investors Group
2010-04-20 03:54:10
Quote: DALLAS and NEW YORK, April 19 /PRNewswire-FirstCall/ -- Jeffrey DavisACCESS PHARMACEUTICALS, INC.ACCP.obNewsMuGard, and discusses the Company's ongoing multi-faceted approach to build value for shareholders. Â The audio interview is now live and can be accessed using the following links:http://www.proactiveinvestors.com/companies/news/5388/jeffrey-davis-ceo-of-access-pharmaceuticals-talks-about-a-product-for-cancer-patients-and-trials-of-orally-administered-insulin-5388.html http://www.youtube...Read article
Access Pharma Collaborates With Leading Oral Mucositis Expert To Further Support MuGard Commercialization Efforts
2010-04-19 02:29:57
Quote: DALLAS and NEW YORK, April 15ACCESS PHARMACEUTICALS, INC.ACCP.obNews), a biopharmaceutical company specializing in products for cancer and supportive care, announced today that it is collaborating with leading expert in oral mucositis ("OM"), Stephen T. Sonisoral mucositis, a debilitating side effect of many anticancer treatments. Â Dr. Sonis will be the primary author on a study protocol aimed at obtaining specific data that will help further broaden the indication for MuGard and support reim...Read article
Access Pharma Announces Successful Completion of First North American MuGard Commercial Production Run
2010-04-14 02:13:58
Quote: DALLAS and NEW YORK, April 13ACCESS PHARMACEUTICALS, INC.ACCP.obNewsMuGard in North America at Accupac, Inc. manufacturing facilities outside Philadelphiaoral mucositis, a debilitating side effect of radiation treatment and chemotherapy. Â "Access is pleased with the pre-launch progress for MuGard, and the successful completion of our first commercial scale production run at Accupac is a key step to making MuGard product available here in North America," states Frank Jacobucci, Vice President ...Read article
Access Pharma Launches Clinical Development Program for Oral Insulin Product
2010-03-31 05:27:47
Quote: DALLAS, March 30ACCESS PHARMACEUTICALS, INC.ACCP.obNewsbioRASI, LLCRussian Federation. Under the agreement, bioRASI will implement the development program necessary to initiate the first-in-man study in Russia and satisfy all regulatory requirements through approval. Â Preclinical and clinical studies will be conducted at highly-respected research facilities within Russian Federation and will follow the International Conference on Harmonisation of Technical Requirements for Registration of Pha...Read article
Access Pharma's Korean Partner Gains Marketing Approval for MuGard
2010-03-29 02:10:59
Quote: DALLAS, March 25ACCESS PHARMACEUTICALS, INC.ACCP.obNewsMuGardâ„¢ProLindacâ„¢Food and Drug Administrationoral mucositis. Â Under the agreement, JCOM is responsible for obtaining the necessary regulatory approvals for MuGard in Korea. As soon as JCOM has completed the additional steps required to import MuGard from the United States, marketing will commence."JCOM is a well-regarded company with an extensive distribution network in Korea," said Jeffrey Davis, CEO of Access Pharmaceuticals...Read article
ACCESS PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
2010-03-24 01:03:45
Quote: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
The following discussion should be read in conjunction with our consolidated
financial statements and related notes included in this Form 10-K.
Access Pharmaceuticals, Inc. (together with our subsidiaries, "We", "Access" or
the "Company") is a Delaware corporation. We are an emerging biopharmaceutical
company focused on developing a range of pharmaceutical products primarily based...Read article
Access Pharmaceuticals Reports Significant Oral Bioavailability of Cobalamin(TM) Oral Insulin in Additional Studies
2010-03-23 01:22:53
Quote: DALLAS, March 11 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC.ACCP.obNewsCobalaminâ„¢ Oral Drug Delivery Technology. Access previously reported that its novel Cobalamin-coated insulin containing nanoparticle formulations delivered orally provided a pharmacological response (lowering of blood glucose levels in animal models) equivalent to greater than 80% of that achieved by insulin delivered subcutaneously. The Company believes the substantial oral bioavailability found underscores ...Read article
Access Pharmaceuticals Reports Significant Oral Bioavailability of Cobalamin(TM) Oral Insulin in Additional Studies
2010-03-12 06:00:23
Quote: DALLAS, March 11 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC.ACCP.obNewsCobalaminâ„¢ Oral Drug Delivery Technology. Access previously reported that its novel Cobalamin-coated insulin containing nanoparticle formulations delivered orally provided a pharmacological response (lowering of blood glucose levels in animal models) equivalent to greater than 80% of that achieved by insulin delivered subcutaneously. The Company believes the substantial oral bioavailability found underscores ...Read article